_id
695fb23bc2e91020a7bd40eb
Ticker
0ABR.LSE
Name
H. Lundbeck A/S
Exchange
LSE
Address
Ottiliavej 9, Valby, Denmark, 2500
Country
UK
Sector
Industry
Currency
DKK
Website
https://www.lundbeck.com
Description
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson's disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson's disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. a strategic. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
Last Close
37.85
Volume
2524
Current Price
38.1
Change
0.6
Last Updated
2026-01-08T13:33:46.861Z
Ipo Date
-
Market Cap
42149253120
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-09-30
Revenue
6279000000
Cost Of Revenue
846000000
Gross Profit
5433000000
Operating Expenses
4648000000
Operating Income
1631000000
Interest Expense
-
Pretax Income
1412000000
Net Income
1101000000
Eps
1.1098790322580645
Dividends Per Share
-
Shares Outstanding
198682000
Income Tax Expense
-
EBITDA
-
Operating Margin
25.975473801560756
Total Other Income Expense Net
-
Cash
3479000000
Short Term Investments
-
Receivables
5609000000
Inventories
4271000000
Total Current Assets
13359000000
Property Plant Equipment
3276000000
Total Assets
53193000000
Payables
4326000000
Short Term Debt
-
Long Term Debt
11924000000
Total Liabilities
28040000000
Equity
25153000000
Bs_currency_symbol
DKK
Depreciation
-
Change In Working Capital
339000000
Cash From Operations
2299000000
Capital Expenditures
171000000
Cash From Investing
-
Cash From Financing
-
Net Change In Cash
836000000
Cf_currency_symbol
DKK
PE
0.1623
PB
1.502612014471435
ROE
4.3772114658291255
ROA
2.069821217077435
FCF
2128000000
Fcf Percent
0.33890746934225197
Piotroski FScore
4
Health Score
65
Deep Value Investing Score
6
Defensive Investing Score
6.5
Dividend Investing Score
3
Economic Moat Investing Score
7.3
Garp Investing Score
5.5
Growth Investing Score
4
Momentum Investing Score
4
Net Net Investing Score
3.5
Quality Investing Score
5.5
Value Investing Score
8.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
6279000000
Quarters > 0 > income Statement > cost Of Revenue
846000000
Quarters > 0 > income Statement > gross Profit
5433000000
Quarters > 0 > income Statement > operating Expenses
4648000000
Quarters > 0 > income Statement > operating Income
1631000000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
1412000000
Quarters > 0 > income Statement > net Income
1101000000
Quarters > 0 > income Statement > eps
1.1098790322580645
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
992000000
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-
Quarters > 0 > income Statement > operating Margin
25.975473801560756
Quarters > 0 > income Statement > total Other Income Expense Net
-
Quarters > 0 > income Statement > currency_symbol
DKK
Quarters > 0 > balance Sheet > cash
3479000000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
5609000000
Quarters > 0 > balance Sheet > inventories
4271000000
Quarters > 0 > balance Sheet > total Current Assets
13359000000
Quarters > 0 > balance Sheet > property Plant Equipment
3276000000
Quarters > 0 > balance Sheet > total Assets
53193000000
Quarters > 0 > balance Sheet > payables
4326000000
Quarters > 0 > balance Sheet > short Term Debt
-
Quarters > 0 > balance Sheet > long Term Debt
11924000000
Quarters > 0 > balance Sheet > total Liabilities
28040000000
Quarters > 0 > balance Sheet > equity
25153000000
Quarters > 0 > balance Sheet > currency_symbol
DKK
Quarters > 0 > cash Flow > net Income
1101000000
Quarters > 0 > cash Flow > depreciation
-
Quarters > 0 > cash Flow > change In Working Capital
339000000
Quarters > 0 > cash Flow > cash From Operations
2299000000
Quarters > 0 > cash Flow > capital Expenditures
171000000
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
-
Quarters > 0 > cash Flow > net Change In Cash
836000000
Quarters > 0 > cash Flow > currency_symbol
DKK
Quarters > 0 > ratios > PE
1.1098790322580645
Quarters > 0 > ratios > PB
1.502612014471435
Quarters > 0 > ratios > ROE
4.3772114658291255
Quarters > 0 > ratios > ROA
2.069821217077435
Quarters > 0 > ratios > FCF
2128000000
Quarters > 0 > ratios > Piotroski FScore
4
Quarters > 0 > ratios > fcf Percent
0.33890746934225197
Quarters > 0 > health Score
65
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
6023000000
Quarters > 1 > income Statement > cost Of Revenue
1091000000
Quarters > 1 > income Statement > gross Profit
4932000000
Quarters > 1 > income Statement > operating Expenses
4452000000
Quarters > 1 > income Statement > operating Income
1571000000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
1238000000
Quarters > 1 > income Statement > net Income
966000000
Quarters > 1 > income Statement > eps
0.9737903225806451
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
992000000
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-
Quarters > 1 > income Statement > operating Margin
26.08334716918479
Quarters > 1 > income Statement > total Other Income Expense Net
-
Quarters > 1 > income Statement > currency_symbol
DKK
Quarters > 1 > balance Sheet > cash
2647000000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
5478000000
Quarters > 1 > balance Sheet > inventories
3898000000
Quarters > 1 > balance Sheet > total Current Assets
12023000000
Quarters > 1 > balance Sheet > property Plant Equipment
3181000000
Quarters > 1 > balance Sheet > total Assets
51803000000
Quarters > 1 > balance Sheet > payables
3980000000
Quarters > 1 > balance Sheet > short Term Debt
-
Quarters > 1 > balance Sheet > long Term Debt
13185000000
Quarters > 1 > balance Sheet > total Liabilities
27613000000
Quarters > 1 > balance Sheet > equity
24190000000
Quarters > 1 > balance Sheet > currency_symbol
DKK
Quarters > 1 > cash Flow > net Income
966000000
Quarters > 1 > cash Flow > depreciation
-
Quarters > 1 > cash Flow > change In Working Capital
39000000
Quarters > 1 > cash Flow > cash From Operations
1629000000
Quarters > 1 > cash Flow > capital Expenditures
127000000
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
-
Quarters > 1 > cash Flow > net Change In Cash
-23000000
Quarters > 1 > cash Flow > currency_symbol
DKK
Quarters > 1 > ratios > PE
0.9737903225806451
Quarters > 1 > ratios > PB
1.562430756510955
Quarters > 1 > ratios > ROE
3.9933856965688306
Quarters > 1 > ratios > ROA
1.864756867362894
Quarters > 1 > ratios > FCF
1502000000
Quarters > 1 > ratios > Piotroski FScore
4
Quarters > 1 > ratios > fcf Percent
0.24937738668437656
Quarters > 1 > health Score
64
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
6235000000
Quarters > 2 > income Statement > cost Of Revenue
1084000000
Quarters > 2 > income Statement > gross Profit
5151000000
Quarters > 2 > income Statement > operating Expenses
4537000000
Quarters > 2 > income Statement > operating Income
1698000000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
1477000000
Quarters > 2 > income Statement > net Income
1152000000
Quarters > 2 > income Statement > eps
1.16140739993951
Quarters > 2 > income Statement > dividends Per Share
943000000
Quarters > 2 > income Statement > shares Outstanding
991900000
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-
Quarters > 2 > income Statement > operating Margin
27.23336006415397
Quarters > 2 > income Statement > total Other Income Expense Net
-
Quarters > 2 > income Statement > currency_symbol
DKK
Quarters > 2 > balance Sheet > cash
2697000000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
5353000000
Quarters > 2 > balance Sheet > inventories
3807000000
Quarters > 2 > balance Sheet > total Current Assets
11857000000
Quarters > 2 > balance Sheet > property Plant Equipment
3186000000
Quarters > 2 > balance Sheet > total Assets
54219000000
Quarters > 2 > balance Sheet > payables
3977000000
Quarters > 2 > balance Sheet > short Term Debt
-
Quarters > 2 > balance Sheet > long Term Debt
14690000000
Quarters > 2 > balance Sheet > total Liabilities
29648000000
Quarters > 2 > balance Sheet > equity
24571000000
Quarters > 2 > balance Sheet > currency_symbol
DKK
Quarters > 2 > cash Flow > net Income
1152000000
Quarters > 2 > cash Flow > depreciation
-
Quarters > 2 > cash Flow > change In Working Capital
-894000000
Quarters > 2 > cash Flow > cash From Operations
632000000
Quarters > 2 > cash Flow > capital Expenditures
111000000
Quarters > 2 > cash Flow > cash From Investing
-
Quarters > 2 > cash Flow > cash From Financing
-
Quarters > 2 > cash Flow > net Change In Cash
-1959000000
Quarters > 2 > cash Flow > currency_symbol
DKK
Quarters > 2 > ratios > PE
1.16140739993951
Quarters > 2 > ratios > PB
1.5380485124740548
Quarters > 2 > ratios > ROE
4.688453868381425
Quarters > 2 > ratios > ROA
2.124716427820506
Quarters > 2 > ratios > FCF
521000000
Quarters > 2 > ratios > Piotroski FScore
3
Quarters > 2 > ratios > fcf Percent
0.08356054530874098
Quarters > 2 > health Score
52
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
5541000000
Quarters > 3 > income Statement > cost Of Revenue
1071000000
Quarters > 3 > income Statement > gross Profit
4470000000
Quarters > 3 > income Statement > operating Expenses
5364000000
Quarters > 3 > income Statement > operating Income
177000000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
680000000
Quarters > 3 > income Statement > net Income
590000000
Quarters > 3 > income Statement > eps
0.5952215951334044
Quarters > 3 > income Statement > dividends Per Share
0
Quarters > 3 > income Statement > shares Outstanding
991227477
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-
Quarters > 3 > income Statement > operating Margin
3.1943692474282623
Quarters > 3 > income Statement > total Other Income Expense Net
-
Quarters > 3 > income Statement > currency_symbol
DKK
Quarters > 3 > balance Sheet > cash
4664000000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
3432000000
Quarters > 3 > balance Sheet > inventories
3983000000
Quarters > 3 > balance Sheet > total Current Assets
13010000000
Quarters > 3 > balance Sheet > property Plant Equipment
3182000000
Quarters > 3 > balance Sheet > total Assets
56976000000
Quarters > 3 > balance Sheet > payables
4370000000
Quarters > 3 > balance Sheet > short Term Debt
-
Quarters > 3 > balance Sheet > long Term Debt
16174000000
Quarters > 3 > balance Sheet > total Liabilities
31966000000
Quarters > 3 > balance Sheet > equity
25010000000
Quarters > 3 > balance Sheet > currency_symbol
DKK
Quarters > 3 > cash Flow > net Income
590000000
Quarters > 3 > cash Flow > depreciation
-
Quarters > 3 > cash Flow > change In Working Capital
349000000
Quarters > 3 > cash Flow > cash From Operations
-1154000000
Quarters > 3 > cash Flow > capital Expenditures
219000000
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
-
Quarters > 3 > cash Flow > net Change In Cash
-3657000000
Quarters > 3 > cash Flow > currency_symbol
DKK
Quarters > 3 > ratios > PE
0.5952215951334044
Quarters > 3 > ratios > PB
1.510026664282287
Quarters > 3 > ratios > ROE
2.3590563774490203
Quarters > 3 > ratios > ROA
1.0355237292895254
Quarters > 3 > ratios > FCF
-1373000000
Quarters > 3 > ratios > Piotroski FScore
2
Quarters > 3 > ratios > fcf Percent
-0.24778920772423751
Quarters > 3 > health Score
42
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
22004000000
Annuals > 0 > income Statement > cost Of Revenue
4230000000
Annuals > 0 > income Statement > gross Profit
17774000000
Annuals > 0 > income Statement > operating Expenses
18734000000
Annuals > 0 > income Statement > operating Income
3270000000
Annuals > 0 > income Statement > interest Expense
113000000
Annuals > 0 > income Statement > pretax Income
3719000000
Annuals > 0 > income Statement > net Income
3143000000
Annuals > 0 > income Statement > eps
3.170816056786933
Annuals > 0 > income Statement > dividends Per Share
694000000
Annuals > 0 > income Statement > shares Outstanding
991227477
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-
Annuals > 0 > income Statement > operating Margin
14.860934375568077
Annuals > 0 > income Statement > total Other Income Expense Net
-
Annuals > 0 > income Statement > currency_symbol
DKK
Annuals > 0 > balance Sheet > cash
4664000000
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
3432000000
Annuals > 0 > balance Sheet > inventories
3983000000
Annuals > 0 > balance Sheet > total Current Assets
13010000000
Annuals > 0 > balance Sheet > property Plant Equipment
3182000000
Annuals > 0 > balance Sheet > total Assets
56976000000
Annuals > 0 > balance Sheet > payables
4370000000
Annuals > 0 > balance Sheet > short Term Debt
-
Annuals > 0 > balance Sheet > long Term Debt
16174000000
Annuals > 0 > balance Sheet > total Liabilities
31966000000
Annuals > 0 > balance Sheet > equity
25010000000
Annuals > 0 > balance Sheet > currency_symbol
DKK
Annuals > 0 > cash Flow > net Income
3143000000
Annuals > 0 > cash Flow > depreciation
1876000000
Annuals > 0 > cash Flow > change In Working Capital
-210000000
Annuals > 0 > cash Flow > cash From Operations
3326000000
Annuals > 0 > cash Flow > capital Expenditures
565000000
Annuals > 0 > cash Flow > cash From Investing
-
Annuals > 0 > cash Flow > cash From Financing
-
Annuals > 0 > cash Flow > net Change In Cash
-331000000
Annuals > 0 > cash Flow > currency_symbol
DKK
Annuals > 0 > ratios > PE
3.170816056786933
Annuals > 0 > ratios > PB
1.510026664282287
Annuals > 0 > ratios > ROE
12.566973210715716
Annuals > 0 > ratios > ROA
5.516357764672844
Annuals > 0 > ratios > FCF
2761000000
Annuals > 0 > ratios > Piotroski FScore
4
Annuals > 0 > ratios > fcf Percent
0.12547718596618795
Annuals > 0 > health Score
67
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
19912000000
Annuals > 1 > income Statement > cost Of Revenue
4485000000
Annuals > 1 > income Statement > gross Profit
15427000000
Annuals > 1 > income Statement > operating Expenses
16717000000
Annuals > 1 > income Statement > operating Income
3195000000
Annuals > 1 > income Statement > interest Expense
54000000
Annuals > 1 > income Statement > pretax Income
2993000000
Annuals > 1 > income Statement > net Income
2290000000
Annuals > 1 > income Statement > eps
2.308442214101725
Annuals > 1 > income Statement > dividends Per Share
576000000
Annuals > 1 > income Statement > shares Outstanding
992010970
Annuals > 1 > income Statement > income Tax Expense
-
Annuals > 1 > income Statement > EBITDA
-
Annuals > 1 > income Statement > operating Margin
16.045600642828443
Annuals > 1 > income Statement > total Other Income Expense Net
-
Annuals > 1 > income Statement > currency_symbol
DKK
Annuals > 1 > balance Sheet > cash
5010000000
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
2965000000
Annuals > 1 > balance Sheet > inventories
4427000000
Annuals > 1 > balance Sheet > total Current Assets
13289000000
Annuals > 1 > balance Sheet > property Plant Equipment
2881000000
Annuals > 1 > balance Sheet > total Assets
37407000000
Annuals > 1 > balance Sheet > payables
4410000000
Annuals > 1 > balance Sheet > short Term Debt
-
Annuals > 1 > balance Sheet > long Term Debt
3714000000
Annuals > 1 > balance Sheet > total Liabilities
15362000000
Annuals > 1 > balance Sheet > equity
22045000000
Annuals > 1 > balance Sheet > currency_symbol
DKK
Annuals > 1 > cash Flow > net Income
2290000000
Annuals > 1 > cash Flow > depreciation
2012000000
Annuals > 1 > cash Flow > change In Working Capital
-929000000
Annuals > 1 > cash Flow > cash From Operations
4080000000
Annuals > 1 > cash Flow > capital Expenditures
501000000
Annuals > 1 > cash Flow > cash From Investing
-
Annuals > 1 > cash Flow > cash From Financing
-
Annuals > 1 > cash Flow > net Change In Cash
1497000000
Annuals > 1 > cash Flow > currency_symbol
DKK
Annuals > 1 > ratios > PE
2.308442214101725
Annuals > 1 > ratios > PB
1.7144757521887048
Annuals > 1 > ratios > ROE
10.387843048310275
Annuals > 1 > ratios > ROA
6.121848851819179
Annuals > 1 > ratios > FCF
3579000000
Annuals > 1 > ratios > Piotroski FScore
4
Annuals > 1 > ratios > fcf Percent
0.1797408597830454
Annuals > 1 > health Score
77
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
18246000000
Annuals > 2 > income Statement > cost Of Revenue
3951000000
Annuals > 2 > income Statement > gross Profit
14295000000
Annuals > 2 > income Statement > operating Expenses
15394000000
Annuals > 2 > income Statement > operating Income
2852000000
Annuals > 2 > income Statement > interest Expense
103000000
Annuals > 2 > income Statement > pretax Income
2474000000
Annuals > 2 > income Statement > net Income
1916000000
Annuals > 2 > income Statement > eps
1.9298180569348904
Annuals > 2 > income Statement > dividends Per Share
397000000
Annuals > 2 > income Statement > shares Outstanding
992839710
Annuals > 2 > income Statement > income Tax Expense
-
Annuals > 2 > income Statement > EBITDA
-
Annuals > 2 > income Statement > operating Margin
15.63082319412474
Annuals > 2 > income Statement > total Other Income Expense Net
-
Annuals > 2 > income Statement > currency_symbol
DKK
Annuals > 2 > balance Sheet > cash
3421000000
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
2709000000
Annuals > 2 > balance Sheet > inventories
3973000000
Annuals > 2 > balance Sheet > total Current Assets
11412000000
Annuals > 2 > balance Sheet > property Plant Equipment
2942000000
Annuals > 2 > balance Sheet > total Assets
37452000000
Annuals > 2 > balance Sheet > payables
4251000000
Annuals > 2 > balance Sheet > short Term Debt
-
Annuals > 2 > balance Sheet > long Term Debt
5096000000
Annuals > 2 > balance Sheet > total Liabilities
16673000000
Annuals > 2 > balance Sheet > equity
20779000000
Annuals > 2 > balance Sheet > currency_symbol
DKK
Annuals > 2 > cash Flow > net Income
1916000000
Annuals > 2 > cash Flow > depreciation
1811000000
Annuals > 2 > cash Flow > change In Working Capital
-405000000
Annuals > 2 > cash Flow > cash From Operations
3519000000
Annuals > 2 > cash Flow > capital Expenditures
820000000
Annuals > 2 > cash Flow > cash From Investing
-
Annuals > 2 > cash Flow > cash From Financing
-
Annuals > 2 > cash Flow > net Change In Cash
1240000000
Annuals > 2 > cash Flow > currency_symbol
DKK
Annuals > 2 > ratios > PE
1.9298180569348904
Annuals > 2 > ratios > PB
1.8204530030800328
Annuals > 2 > ratios > ROE
9.220847971509698
Annuals > 2 > ratios > ROA
5.115881661860515
Annuals > 2 > ratios > FCF
2699000000
Annuals > 2 > ratios > Piotroski FScore
4
Annuals > 2 > ratios > fcf Percent
0.14792283240162227
Annuals > 2 > health Score
72
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
16299000000
Annuals > 3 > income Statement > cost Of Revenue
3648000000
Annuals > 3 > income Statement > gross Profit
12651000000
Annuals > 3 > income Statement > operating Expenses
14289000000
Annuals > 3 > income Statement > operating Income
2010000000
Annuals > 3 > income Statement > interest Expense
153000000
Annuals > 3 > income Statement > pretax Income
1581000000
Annuals > 3 > income Statement > net Income
1318000000
Annuals > 3 > income Statement > eps
6.634914823676862
Annuals > 3 > income Statement > dividends Per Share
497000000
Annuals > 3 > income Statement > shares Outstanding
198646107
Annuals > 3 > income Statement > income Tax Expense
-
Annuals > 3 > income Statement > EBITDA
-
Annuals > 3 > income Statement > operating Margin
12.33204491073072
Annuals > 3 > income Statement > total Other Income Expense Net
-
Annuals > 3 > income Statement > currency_symbol
DKK
Annuals > 3 > balance Sheet > cash
2279000000
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
2459000000
Annuals > 3 > balance Sheet > inventories
2775000000
Annuals > 3 > balance Sheet > total Current Assets
8612000000
Annuals > 3 > balance Sheet > property Plant Equipment
2907000000
Annuals > 3 > balance Sheet > total Assets
34653000000
Annuals > 3 > balance Sheet > payables
3914000000
Annuals > 3 > balance Sheet > short Term Debt
-
Annuals > 3 > balance Sheet > long Term Debt
4783000000
Annuals > 3 > balance Sheet > total Liabilities
16374000000
Annuals > 3 > balance Sheet > equity
18279000000
Annuals > 3 > balance Sheet > currency_symbol
DKK
Annuals > 3 > cash Flow > net Income
1318000000
Annuals > 3 > cash Flow > depreciation
1710000000
Annuals > 3 > cash Flow > change In Working Capital
-305000000
Annuals > 3 > cash Flow > cash From Operations
2272000000
Annuals > 3 > cash Flow > capital Expenditures
612000000
Annuals > 3 > cash Flow > cash From Investing
-
Annuals > 3 > cash Flow > cash From Financing
-
Annuals > 3 > cash Flow > net Change In Cash
-1674000000
Annuals > 3 > cash Flow > currency_symbol
DKK
Annuals > 3 > ratios > PE
6.634914823676862
Annuals > 3 > ratios > PB
0.4140498209256524
Annuals > 3 > ratios > ROE
7.210460090814596
Annuals > 3 > ratios > ROA
3.803422503102184
Annuals > 3 > ratios > FCF
1660000000
Annuals > 3 > ratios > Piotroski FScore
4
Annuals > 3 > ratios > fcf Percent
0.10184673906374624
Annuals > 3 > health Score
64
Valuation > metrics > PE
0.1623
Valuation > metrics > PB
1.502612014471435
Valuation > final Score
100
Valuation > verdict
49.2% Undervalued
Profitability > metrics > ROE
4.3772114658291255
Profitability > metrics > ROA
8.24163485290815
Profitability > metrics > Net Margin
0.1753463927376971
Profitability > final Score
60
Profitability > verdict
Adequate
Risk > metrics > Debt Equity
1.1147775613246929
Risk > final Score
50
Risk > verdict
High
Liquidity > metrics > Current Ratio
3.0880721220527048
Liquidity > metrics > Quick Ratio
2.1007859454461397
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
100
Prev Valuations > 1
100
Prev Valuations > 2
100
Prev Profitabilities > 0
56
Prev Profitabilities > 1
66
Prev Profitabilities > 2
34
Prev Risks > 0
50
Prev Risks > 1
50
Prev Risks > 2
50
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T23:13:07.402Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-02-04
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
AfterMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson's disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson's disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. a strategic. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
Stock Price
DKK0.00
increase compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/A(Last Updated 2025-09-30)
Health Score
Price to Earnings Ratio (P/E)
-
Very High
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very High
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of H. Lundbeck A/S
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
—
Date
—
EPS Actual
—
EPS Estimate
—
EPS Difference
—
Surprise Percent
undefined%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
DKK 0
Cost Of Revenue
DKK 0
Gross Profit
DKK 0
Operating Expenses
DKK 0
Operating Income
DKK 0
Interest Expense
DKK 0
Pretax Income
DKK 0
Net Income
DKK 0
Income Tax Expense
DKK 0
EBITDA
DKK 0
Total Other Income Expense Net
DKK 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
DKK 0
Short Term Investments
DKK 0
Receivables
DKK 0
Inventories
DKK 0
Total Current Assets
DKK 0
Property Plant Equipment
DKK 0
Total Assets
DKK 0
Payables
DKK 0
Short Term Debt
DKK 0
Long Term Debt
DKK 0
Total Liabilities
DKK 0
Equity
DKK 0
(Last Updated 2025-09-30)
Net Income
DKK 0
Depreciation
DKK 0
Change In Working Capital
DKK 0
Cash From Operations
DKK 0
Capital Expenditures
DKK 0
Cash From Investing
DKK 0
Cash From Financing
DKK 0
Net Change In Cash
DKK 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.